Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

A technology for autism and derivatives, which is applied in the field of carbamoylcyclohexane derivatives for the treatment of autism spectrum disorders, and can solve problems such as reduced function

Pending Publication Date: 2021-11-19
RICHTER GEDEON NYRT
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Further studies reported that 5-hydroxytryptamine 5-HT in the peripheral and brain of ASD patients 2 Type

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
  • Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
  • Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] In one aspect, the present application relates to trans-N-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl disclosed in WO 2005 / 012266A1 ]-N',N'-dimethylurea hydrochloride (cariprazine) and trans-N-[4-{2-[4-(2,3-dichloro-phenyl)-piperazine -1-yl]-ethyl}-cyclohexyl]-morpholine-4-carboxamide hydrochloride (compound 2). Cariprazine has shown great benefit on ASD symptoms in animal models. These results suggest that cariprazine, its close analogs and derivatives may have therapeutic effects against the symptoms of ASD in human patients.

[0025] In one aspect, the application relates to the use of cariprazine, its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations for the treatment of a condition selected from Asperger's syndrome, Atypical autism (also known as combined mental developmental disorder not otherwise specified; PDD-NOS), Rett syndrome, childhood schizotypal disorder, attention deficit hyperactivity disorde...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to trans-N-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-N',N'-dimethylurea (cariprazine), its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations for use in the treatment of symptoms of autism spectrum disorder in general, and preferably the object of the present invention is to treat one or more symptoms of autism. Furthermore, it was also found that cariprazine, its salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations are suitable for treatment of conditions such as Asperger's syndrome, atypical autism (otherwise known as pervasive developmental disorder not otherwise specified; PDD-NOS), Rett syndrome, childhood disintegrative disorder, attention deficit hyperactivity disorder (ADHD) and sensory integration dysfunction.

Description

technical field [0001] The present invention relates to trans-N-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl] for use in the treatment of symptoms of autism spectrum disorder -N',N'-dimethylurea (cariprazine), salts, close analogs, derivatives, pharmaceutical compositions, metabolites and combinations thereof. Background technique [0002] Autism Spectrum Disorder (ASD) is a complex, very challenging and prevalent neurodevelopmental disorder with a frequency of 1:34-1:77 (average 1 :59) (CDC Morbidity and Mortality Weekly Report Surveillance Summaries, April 27, 2018 / 67(6):1-23 "CDC Morbidity and Mortality Weekly Report Surveillance Summaries, April 27, 2018 / 67(6): 1-23"). According to several epidemiological studies, the median prevalence estimate for ASD in 2012 was 62 / 10,000 (Elsabbagh et al., Autism Res. 2012, 5: 160-179). As such, ASD is today recognized as a global, common, lifelong neurodevelopmental disorder affecting about 1% of children and adult...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/496A61K31/5377A61K45/06A61P25/00
CPCA61K31/496A61K31/5377A61K45/06A61P25/00A61K31/495A61P25/18
Inventor V·罗曼N·阿德哈姆-帕兰吉W·罗杰厄利P·珀-杰杨
Owner RICHTER GEDEON NYRT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap